[HOXA13在Ⅱa期食管鳞状细胞癌中的上调及其对预后的影响]
[Up-regulation of HOXA13 in esophageal squamous cell carcinoma of stage IIa and its effect on the prognosis].
作者信息
Yan Wan-Pu, Shen Lu-Yan, Gu Zhen-Dong, Chen Ke-Neng
机构信息
Department of Thoracic Surgery I, Peking University School of Oncology, Beijing Cancer Hospital, Beijing 100036, China.
出版信息
Zhonghua Wei Chang Wai Ke Za Zhi. 2009 Jan;12(1):20-3.
OBJECTIVE
To investigate the expression of HOXA13 gene in stage-II(a esophageal squamous cell carcinoma(ESCC), and to evaluate its relationship with clinicopathological characteristics and prognosis.
METHODS
The expression of HOXA13 was examined by immunohistochemistry(IHC) in specimens from 39 patients with ESCC of stage-II(a, who underwent resection from 1995 to 2002. SPSS software was used to analyze the relationship between HOXA13 expression and clinicopathological characteristics and prognosis of patients.
RESULTS
The expression of HOXA13 protein was detected in ESCC tissue, and the positive rate was 61.5%. The median survival time of patients without HOXA13 expression(>72 months) was significantly longer than those with HOXA13 expression (24 months)( P=0.023). Multivariate analysis showed that HOXA13 expression was independent predictor of disease-free survival time of patients with ESCC.
CONCLUSION
The expression of HOXA13 can be detected in ESCC and is a negative independent predictor of disease-free survival, which implies that HOXA13 might play a role in ESSC, and may be used as a clinical tumor marker of ESCC.
目的
探讨HOXA13基因在Ⅱ（a）期食管鳞状细胞癌（ESCC）中的表达情况，并评估其与临床病理特征及预后的关系。
方法
采用免疫组织化学（IHC）法检测1995年至2002年间接受手术切除的39例Ⅱ（a）期ESCC患者标本中HOXA13的表达。运用SPSS软件分析HOXA13表达与患者临床病理特征及预后的关系。
结果
在ESCC组织中检测到HOXA13蛋白表达，阳性率为61.5%。HOXA13无表达患者的中位生存时间（>72个月）显著长于有表达患者（24个月）（P = 0.023）。多因素分析表明，HOXA13表达是ESCC患者无病生存时间的独立预测因素。
结论
ESCC中可检测到HOXA13表达，且是无病生存的负性独立预测因素，这表明HOXA13可能在ESCC中发挥作用，有望作为ESCC的临床肿瘤标志物。
Zotero 插件